StemCell Institute (JP:7096)
:7096
Want to see JP:7096 full AI Analyst Report?
7096 Stock Chart & Stats
¥793.00
¥110.00(8.02%)
At close: 4:00 PM EST
¥793.00
¥110.00(8.02%)
Day’s Range― - ―
52-Week Range¥724.00 - ¥1,347.00
Previous CloseN/A
Volume70.10K
Average Volume (3M)28.64K
Market Cap
¥7.56B
Enterprise Value¥4.76B
Total Cash (Recent Filing)¥2.71B
Total Debt (Recent Filing)¥497.26M
Price to Earnings (P/E)33.5
Beta0.46
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)24.46
Shares Outstanding10,246,600
10 Day Avg. Volume23,150
30 Day Avg. Volume28,640
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)5.29
Price to Sales (P/S)5.19
P/FCF Ratio-1.37K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.9
Revenue Forecast (FY)¥3.20B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin StrengthSustained revenue growth combined with very high gross margin and improving net margin indicates durable product economics and pricing power. These margins support reinvestment into R&D and commercialization, increasing the firm's ability to fund long-term growth without eroding profitability.
Low Leverage / Capital StructureA low debt burden provides lasting financial flexibility for a biotech company, reducing solvency risk and enabling investment in clinical programs or partnerships. This capital structure supports sustained operations and strategic choices with less pressure from fixed financial costs.
Operating Cash ConversionOperating cash generation above net income shows earnings convert to cash well, a durable indicator of earnings quality. Reliable operating cash allows the company to fund ongoing R&D and operations, reducing reliance on external financing for routine growth.
Bears Say
Negative Free Cash FlowNegative free cash flow is a structural concern if persistent: it can force reliance on external financing or equity raises, dilute shareholders, or require cutbacks in investment. Over months this constrains strategic flexibility and may slow program advancement or commercialization plans.
Weak EPS TrendA large decline in EPS growth signals volatility or one-off hits to profitability, reducing the firm's internal capacity to fund R&D and strategic initiatives. Persistently weak EPS growth undermines long-term earnings momentum and raises execution risk for future projects.
Moderate Return On EquityAn ROE in the mid-teens suggests the company is not extracting maximum value from shareholder capital versus high-performing peers. Over a multi-quarter horizon this limits potential shareholder returns and may indicate room to improve operational efficiency or capital allocation decisions.
StemCell Institute News
7096 FAQ
What was StemCell Institute’s price range in the past 12 months?
StemCell Institute lowest stock price was ¥724.00 and its highest was ¥1347.00 in the past 12 months.
What is StemCell Institute’s market cap?
StemCell Institute’s market cap is ¥7.56B.
When is StemCell Institute’s upcoming earnings report date?
StemCell Institute’s upcoming earnings report date is May 13, 2026 which is in 2 days.
How were StemCell Institute’s earnings last quarter?
StemCell Institute released its earnings results on Feb 12, 2026. The company reported ¥6.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥6.12.
Is StemCell Institute overvalued?
According to Wall Street analysts StemCell Institute’s price is currently Overvalued.
Does StemCell Institute pay dividends?
StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here
What is StemCell Institute’s EPS estimate?
StemCell Institute’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemCell Institute have?
StemCell Institute has 10,246,600 shares outstanding.
What happened to StemCell Institute’s price movement after its last earnings report?
StemCell Institute reported an EPS of ¥6.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.296%.
Which hedge fund is a major shareholder of StemCell Institute?
Currently, no hedge funds are holding shares in JP:7096
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemCell Institute
StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―